The survival analysis using a Cox proportional hazards model demonstrated benefit for PrimeC with a statistically significant 65% reduction in risk of death (hazard ratio: 0.35; p ...

Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating ...

NS Pharma, Inc. (NS Pharma, New Jersey, USA; President, Yukiteru Sugiyama ), a biopharmaceutical leader in rare diseases and subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today ...

Positive data from EXPERTS-ALS could accelerate RT1999 towards a registration trial; RT1999 to be presented as a poster ...

Shares of Dyne Therapeutics gained after the company shared positive data from a continuing trial of a potential Duchenne muscular dystrophy treatment. The stock rose 14%, to $16.93, midday Monday.

Parent Project Muscular Dystrophy (PPMD), the leading U.S. non-profit driving Duchenne and Becker muscular dystrophy care, research, and advocacy efforts, with a group of more than 120 advocates, will ...

The Food and Drug Administration’s vaccine chief, Dr. Vinay Prasad, will depart the agency next month, an FDA spokesperson ...

Steph is an ambassador for Muscular Dystrophy UK and will speak about his sporting experiences at a free networking day on ...

Santhera Pharmaceuticals is leveraging fresh clinical evidence to strengthen the market position of its flagship therapy, Agamree. The company recently presente ...

Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting ...

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of ...

Patients treated with low dose BB-301 and high dose BB-301 experienced significant improvements in throat closure, throat emptying, and total dysphagic symptom burden - OPMD Patients treated with low ...